Analysts Offer Predictions for RYTM FY2027 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju expects that the company will earn $1.06 per share for the year. HC Wainwright currently has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

RYTM has been the topic of a number of other research reports. Canaccord Genuity Group cut their target price on shares of Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating on the stock in a research note on Monday. TD Cowen reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Wall Street Zen downgraded Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Stifel Nicolaus set a $131.00 target price on Rhythm Pharmaceuticals in a research report on Thursday. Finally, Zacks Research raised Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.57.

Rhythm Pharmaceuticals Price Performance

NASDAQ RYTM opened at $94.94 on Tuesday. The company has a market capitalization of $6.48 billion, a price-to-earnings ratio of -30.53 and a beta of 2.06. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $122.20. The company’s fifty day moving average price is $103.54 and its two-hundred day moving average price is $103.57.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. The business had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business’s quarterly revenue was up 36.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.72) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its stake in shares of Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after purchasing an additional 141 shares during the period. SBI Securities Co. Ltd. grew its position in Rhythm Pharmaceuticals by 73.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after buying an additional 145 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Rhythm Pharmaceuticals by 1,110.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock valued at $35,000 after buying an additional 322 shares during the period. Finally, GAMMA Investing LLC increased its stake in Rhythm Pharmaceuticals by 48.6% during the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after buying an additional 118 shares during the period.

Insider Transactions at Rhythm Pharmaceuticals

In other news, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares of the company’s stock, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 25,003 shares of company stock valued at $2,589,015 over the last three months. 6.10% of the stock is currently owned by company insiders.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: TRANSCEND Phase 3 clinical update: additional 52-week data showed an 18.8% placebo‑adjusted BMI reduction in patients with acquired hypothalamic obesity and Rhythm reiterated a March 20, 2026 PDUFA goal date for the sNDA for setmelanotide — a clear regulatory catalyst if approval is granted. Rhythm Announces Additional Positive Data from Phase 3 TRANSCEND trial
• Positive Sentiment: Several analysts raised or set high price targets this week (including raises reported to $176 and $143), signaling continued bullish conviction from some sell‑side firms and implying significant upside versus current levels. Price Target Raised to $176 Price Target Raised to $143
• Positive Sentiment: Canaccord maintained a Buy rating with a $140 target (a small trim from $141) — still implying material upside and signaling continued buy-side interest. Given New $140.00 Price Target at Canaccord
• Positive Sentiment: HC Wainwright issued an FY2027 EPS projection of $1.06 and kept a Buy rating, suggesting some analysts now expect the company to move toward positive earnings in the medium term (this contrasts with current consensus loss estimates).
• Neutral Sentiment: Valuation discussion: market commentary and a Yahoo Finance piece reviewed RYTM’s valuation after recent pullback, highlighting both the clinical/regulatory upside and higher beta/valuation risk — useful context for investors weighing risk/reward. A Look At Rhythm Pharmaceuticals (RYTM) Valuation
• Negative Sentiment: Offsetting note: HC Wainwright trimmed its price target to $110 (from $125), which reduces one analyst’s implied upside and is a reminder of divergent analyst views on near‑term valuation. Price Target Cut to $110.00 by HC Wainwright

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.